Research Article| Volume 17, ISSUE 3, P402-412, May 1995

Download started.


Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia

      This paper is only available as a PDF. To read, Please Download here.


      The long-term efficacy and safety of risperidone were evaluated in patients with chronic schizophrenia in an open-label study. Thirty-two patients received risperidone for 1 year and 19 of the 32 received risperidone for 2 years. The mean dose of risperidone was 9.4 mg/d in the 1-year follow-up and 8 mg/d in the 2-year follow-up. At the end of 1 and 2 years, improvements were found in total scores on the Positive and Negative Syndrome Scale (PANSS), on four PANSS factors (positive, negative, excited, and cognitive), and the Clinical Global Impression scale. Severity of extrapyramidal symptoms (based on scores on the Extrapyramidal Symptom Rating Scale) was also reduced. Clinical improvement (defined as a 20% or more reduction in total PANSS scores) was shown by 54% of the patients at end point. Social functioning (as assessed by using the modified Straus/Carpenter scale) was significantly improved after 2 years. Number of days spent in hospitals was significantly reduced during the 2 years of treatment, and the number of days in treatment (group) homes significantly increased. It is concluded that treatment with risperidone for 1 and 2 years is associated with significant reductions in symptoms of schizophrenia, improved social functioning, and reduction in days spent in the hospital.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Peuskens J. The Risperidone Study Group. Risperidone in the treatment of chronic schizophrenic patients: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. In press.

        • Borison RL
        • Pathiraja AP
        • Diamond BI
        • et al.
        Risperidone: Clinical safety and efficacy in schizophrenia.
        Psychopharmacol Bull. 1992; 28: 213-218
        • Chouinard G
        • Jones B
        • Remington G
        • et al.
        A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
        J Clin Psychopharmacol. 1993; 13: 25-40
        • Marder SR
        • Meibach RC
        Risperidone in the treatment of schizophrenia.
        Am J Psychiatry. 1994; 151: 825-835
        • American Psychiatric Association
        Third Edition. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC1987 (Revised)
        • Kay SR
        • Fizbein A
        • Opler LA
        The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
        Schizophr Bull. 1987; 13: 261-276
        • Lindström E
        • von Knorring L
        Principal component analysis of the Swedish version of the Positive and Negative Syndrome Scale for schizophrenia.
        Nord J Psychiatry. 1999; 47: 257-263
        • Lindström E
        • von Knorring L
        Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol.
        Pharmacopsychiatry. 1993; 27: 108-113
        • Lindenmayer JP
        • Bernstein-Hyman R
        • Grochowski S
        Five-factor model of schizophrenia; initial validation.
        J Nerv Ment Dis. 1994; 182: 631-638
      2. Guy W ECDEU Assessment Manual for Psychopharmacology. National Institute of Mental Health, Rockville, Md1976 (Publication ADM 76-338)
        • Chouinard G
        • Ross-Chouinard A
        • Annable L
        • Jones BD
        Extrapyramidal Symptom Rating Scale.
        Can J Neurol Sci. 1980; 7: 233
        • Strauss JS
        • Carpenter WT
        The prediction of outcome in schizophrenia.
        Arch Gen Psychiatry. 1972; 27: 739-746
        • Hogarty GE
        • Goldberg SC
        • Schooler NR
        • et al.
        Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-year relapse rates.
        Arch Gen Psychiatry. 1974; 31: 603-608
        • Schooler NR
        • Levine J
        • Severe JB
        • et al.
        Prevention of relapse in schizophrenia: An evaluation of fluphenazine decanoate.
        Arch Gen Psychiatry. 1980; 37: 16-24
        • Hogarty GE
        • Schooler NR
        • Ulrich R
        • et al.
        Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.
        Arch Gen Psychiatry. 1979; 36: 1283-1294
        • Keepers GA
        • Clappison VJ
        • Casey DE
        Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.
        Arch Gen Psychiatry. 1983; 40: 1113-1117
        • Governmental Committee of Psychiatry
        Welfare and Free Choice. Allmänna Förlaget, SOU, Stockholm, Sweden1992: 73
        • Addington DE
        • Jones B
        • Bloom D
        • et al.
        Reduction in hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study.
        Clin Ther. 1993; 15: 917-926